EU grants 10 years market exclusivity to Ascendis Pharma's TransCon CNP for achondroplasia treatment

Ascendis Pharma's once-weekly TransCon CNP (navepegritide) received a positive opinion from the European Medicines Agency's Committee for Orphan Medicinal Products, recommending 10 years of market exclusivity upon approval in the EU. This treatment targets achondroplasia in children and follows a positive marketing authorization recommendation by the EMA's CHMP. The European Commission's final decision is expected in Q4 2026, with an anticipated launch in Germany in Q1 2027 under the brand name YUVIWEL. This approval would provide a novel treatment option addressing serious complications of achondroplasia, a rare genetic disorder affecting bone growth and other bodily functions.

Ascendis Pharma A/S holds a market capitalization of $16.67 billion as of November 6, 2026, 20:11 WIB, with a trading volume of 557,574 shares on Pluang. The stock price remains stable at USD 253.45, showing no change in the past day. Pluang investors currently show full buying interest with 100% buy orders and a typical hold time of 57 days, reflecting steady engagement with the stock amid the company's regulatory progress in the EU.